Proposed LCDs

When there are Proposed Local Coverage Determinations (LCDs) that are in the comment period, this webpage will provide a summary of comments received and Noridian's response. This information will remain on this webpage for at least six months.

Status Indicators

D = Proposed under development, not yet released for comment
C = Proposed LCD released for comment
E = Formal comment period has ended; comments now being considered
F = Final new/revised LCD has been issued for notice
A = Active policy: notice period complete and the policy is in effect

Send Proposed LCD Comments to:

Mail:
Noridian Medicare JE Part B
Attention: Proposed LCD Comments
PO Box 6781
Fargo, ND 58108-6781
Email: policydraft@noridian.com

 
Proposed LCD and LCA Title Release Date of Proposed LCD for Comment End Date for Comment Period Current Status Comments / Responses Date of Release for Notice Link to Final LCD
Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
06/15/23 07/29/23 F View 09/28/23 View
Cervical Fusion

Billing and Coding: Cervical Fusion
01/18/24 03/02/24 C      
Facet Joint Interventions for Pain Management

Billing and Coding: Facet Joint Interventions for Pain Management
01/18/24 03/02/24 C      
Intraosseous Basivertebral Nerve Ablation

Billing and Coding: Intraosseous Basivertebral Nerve Ablation
08/03/23 09/16/23 F View 12/14/23 View

MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

Billing and Coding: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

08/31/23 10/14/23 C      
MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
07/07/22 08/20/22 F View 06/22/23 View
MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy

Billing and Coding: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
08/31/23 10/14/23 C      
MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

Billing and Coding: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
10/06/22 11/19/22 F View 08/31/23 View
MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

Billing and Coding: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
06/08/23 07/22/23 C      
MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules

Billing and Coding: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
08/31/23 10/14/23 C      
MolDX: Molecular Testing for Solid Organ Allograft Rejection

Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection
08/10/23 09/23/23 E      
Respiratory Care

Billing and Coding: Respiratory Care
06/15/23 07/29/23 F View 09/21/23 View
Transurethral Waterjet Ablation of the Prostate

Billing and Coding: Transurethral Waterjet Ablation of the Prostate
06/15/23 07/29/23 F View 12/14/23 View
Trigger Point Injections (TPI)

Billing and Coding: Trigger Point Injections (TPI)
08/17/23 09/30/23 F  View  02/15/24  View
Last Updated Feb 15 , 2024